Themis Medicare Q4 FY26: Revenue ₹76.53 Cr, PAT ₹8.89 Cr
Q4 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹77Cr
- +6.7% YoY
- −15.1% QoQ
- Net profit
- ₹9Cr
- Turned profitable YoY
- −11.9% QoQ
- Margin
- 4.91%
- +15.7 pp YoY
- −6 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Themis Medicare Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Q4 FY26 EBITDA: ₹3.76 crore (up from a loss of ₹5.78 crore in Q4 FY25), margin 4.92% (vs. -8.07% YoY).
From Themis Medicare Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8).
- FY26 Net Revenue: ₹342.24 crore, down 15.6% YoY from ₹405.51 crore in FY25 (Page 9).
- Quarterly Revenue trend: Q1 FY26 ₹97.6 crore, Q2 FY26 ₹78.0 crore, Q3 FY26 ₹90.1 crore, Q4 FY26 ₹76.5 crore (Page 7).
2 more points from Themis Medicare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The presentation mentions vertically integrated manufacturing facilities at Haridwar, Hyderabad, and Vapi with state-of-art capabilities for formulations and synthetic APIs.
- Capacity details:
- Formulations (Haridwar): Tablets (520 mn), Ointments (9 mn tubes), Ampoules (36 mn), Vials (12 mn), Pre-filled syringes (6 mn) per annum.
2 more points from Themis Medicare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Themis Medicare Ltd — Quarterly revenue & net profit
Themis Medicare Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 77 | 72 | +6.7% | 90 | -15.1% |
| Operating profit (EBITDA) | 4 | -8 | — | 10 | -61.6% |
| Operating margin | 4.91% | -10.74% | +15.7 pp | 10.87% | -6 pp |
| Profit before tax | 9 | -11 | — | 10 | -12.8% |
| Net profit (PAT) | 9 | -10 | — | 10 | -11.9% |
| EPS (₹) | 0.97 | -1.05 | — | 1.10 | -11.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹90 Cr, net profit ₹7 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Themis Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Themis Medicare Ltd Q4 FY26 results?
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Q4 FY26 EBITDA: ₹3.76 crore (up from a loss of ₹5.78 crore in Q4 FY25), margin 4.92% (vs. -8.07% YoY).
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Is Themis Medicare Ltd planning capital expenditure?
The presentation mentions vertically integrated manufacturing facilities at Haridwar, Hyderabad, and Vapi with state-of-art capabilities for formulations and synthetic APIs.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
